Covid vaccines saved lives. Lots of them. Research by the World Health Organization (WHO) now puts the number at 475,000 in the UK with many more kept out of hospital or off a ventilator.

Eli Lilly also signed a major deal, agreeing to buy Scorpion Therapeutics ... nor is there any vaccine against it. A treatment for norovirus is unlikely to be developed because the viral infection ...

Johnson & Johnson made the biggest splash, acquiring neurology leader Intra-Cellular Therapies for $14.6 billion, while GSK picked up precision therapy specialist IDRx for $1B upfront and Eli Lilly ...

On the clinical side, we saw GSK shell out just over $1 billion for gastrointestinal cancer specialists IDRx, while Eli Lilly, flush with its Mounjaro cash, paid $2.5 billion for Scorpion ...

Babies are supposed to receive vaccines that protect against about 15 different infectious diseases. Most require more than one dose, which amounts to nearly 30 jabs by age two. Parents may be ...

Ah, the scorpion lollipop, a symbol of the Sonoran Desert. I like them, if only for the campiness of the dark, goth-looking scorpion encased unhappily in a gentle green, pink or blue. That said, ...

Eli Lilly has agreed to acquire Scorpion Therapeutics’ breast cancer treatment program for up to $2.5 billion in cash. The drugmaker said Monday it is acquiring Scorpion and its STX-478 program ...

Eli Lilly is reenergizing its attempt to challenge Novartis and Roche for a breast cancer market, kicking off the J.P. Morgan Healthcare Conference with a deal to buy Scorpion Therapeutics ...

SAN FRANCISCO — Eli Lilly said Monday it would acquire a cancer program from startup Scorpion Therapeutics in a deal worth up to $2.5 billion, as the Indianapolis company broadens its pipeline.

SAN FRANCISCO — Eli Lilly’s chief scientific officer said Monday that the company purchased a cancer drug from the startup Scorpion Therapeutics because Scorpion’s drug appeared better than ...

We look forward to leveraging the great work of the Scorpion team to date, along with Lilly's deep expertise in breast cancer, to further advance STX-478 with speed and focus." Under the terms of ...